Cyrus Harmon Sells 5,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $10.92, for a total value of $54,600.00. Following the completion of the sale, the director now owns 806,283 shares of the company’s stock, valued at $8,804,610.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Cyrus Harmon also recently made the following trade(s):

• On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $9.51, for a total value of $142,650.00.
• On Thursday, March 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.97, for a total value of $219,400.00.
• On Thursday, February 29th, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $12.41, for a total value of $310,250.00.

Olema Pharmaceuticals Stock Performance

Shares of OLMA stock opened at $10.85 on Thursday. Olema Pharmaceuticals, Inc. has a fifty-two week low of $5.02 and a fifty-two week high of $17.79. The firm has a market capitalization of $606.84 million, a price-to-earnings ratio of -5.02 and a beta of 2.10. The stock’s 50-day simple moving average is $11.39 and its 200-day simple moving average is $12.84.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Monday, March 11th. The company reported ($0.49) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.49). As a group, equities analysts forecast that Olema Pharmaceuticals, Inc. will post -2.34 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on OLMA. Citigroup began coverage on Olema Pharmaceuticals in a research note on Tuesday, January 30th. They issued a “buy” rating and a $20.00 target price on the stock. The Goldman Sachs Group began coverage on Olema Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $24.00 target price on the stock. Finally, Capital One Financial reiterated an “overweight” rating on shares of Olema Pharmaceuticals in a research note on Thursday, February 22nd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $21.43.

Institutional Investors Weigh In On Olema Pharmaceuticals

Large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio purchased a new stake in shares of Olema Pharmaceuticals during the third quarter worth about $35,000. China Universal Asset Management Co. Ltd. purchased a new stake in Olema Pharmaceuticals in the fourth quarter valued at approximately $89,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Olema Pharmaceuticals in the fourth quarter valued at approximately $130,000. SG Americas Securities LLC purchased a new stake in Olema Pharmaceuticals in the third quarter valued at approximately $142,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in Olema Pharmaceuticals in the third quarter valued at approximately $164,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.